PEA (Palmitoylethanolamide)vsPhosphatidylserine

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.

PS is a structural component of neuronal membranes, maintaining membrane fluidity and supporting receptor function, ion channel activity, and neurotransmitter release. It localizes preferentially to the inner leaflet of the plasma membrane via flippase enzymes (P4-ATPases), where it serves as a cofactor for protein kinase C (PKC) isoforms alpha, beta, and gamma — PKC activation phosphorylates substrates including MARCKS and GAP-43, critical for synaptic plasticity and memory consolidation. PS modulates the HPA axis via glucocorticoid receptor feedback, reducing cortisol by 15-30% in stressed individuals. It facilitates choline transport via high-affinity choline transporter (CHT1) into presynaptic terminals, supporting acetylcholine synthesis by choline acetyltransferase. PS also regulates NMDA receptor function and supports Na+/K+-ATPase activity. Downstream, PS enhances CREB phosphorylation and BDNF expression in hippocampal neurons.